Allon Therapeutics Inc.
TSX : NPC

Allon Therapeutics Inc.

October 09, 2007 09:30 ET

Allon Adds Additional Efficacy Evidence and Publishes Important Review of Alzheimer's

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Oct. 9, 2007) - Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection Company™, announced today that the journal Expert Opinions in Investigational Drugs recently published an expert review by Allon's scientific team of novel drugs in development for Alzheimer's disease. The invited review "Looking for novel ways to treat the hallmarks of Alzheimer's disease", describes a range of new drugs but focuses on strategies that break new ground. The review shows clearly that the high potential approaches are those dealing with the underlying causes of the disease.

Additionally, Allon announced today the publication of new preclinical data confirming the central importance of Activity Dependent Neuroprotective Protein (ADNP) in learning, memory, and the regulation of genes involved in normal brain development. ADNP is the protein from which Allon's neuroprotective product AL-108 originates and is protected by Allon's intellectual property estate. Previous work has shown that ADNP is essential for survival and these new findings confirm that a reduction in ADNP production has consequences for the expression of a number of genes that are critical to the normal function and development of the brain. The study was published in the August 2007 edition of the Journal of Pharmacology and Experimental Therapeutic (JPET). The results were further complemented by another study on ADNP mechanism of action published in The Journal of Biological Chemistry (JBC) in September.

These three publications highlight the importance of Allon's drug platforms using natural neuroprotective mechanisms to generate safe and effective treatments for a range of neurodegenerative conditions. These treatments are clearly focused on the underlying causes of neurodegenerative disease. Of key importance is that AL-108 has effects on both plaques and tangles in models of Alzheimer's disease and this effect is reinforced by this new study of ADNP deficiency.

The principal findings from the JPET study are:

- ADNP-deficient mice show accumulation of significant increases in phosphorylated tau, tangle-like structures and neurodegeneration;

- ADNP-deficient mice are defective in their ability to learn and remember new tasks;

- ADNP is a natural neuroprotectant in the brain since its loss is clearly detrimental to the normal function and development of brain tissue; and

- AL-108 (NAPVSIPQ) can provide protection against ADNP loss.

About Allon

Allon Therapeutics Inc. is a clinical-stage biotechnology company developing treatments for major neurodegenerative conditions. Allon has 3 Phase II human efficacy trials underway pursuing three large underserved markets: Alzheimer's disease, schizophrenia and cognitive impairment. The Company is listed on the Toronto Stock Exchange under the trading symbol "NPC" (Neuroprotection Company™) and based in Vancouver. For additional information please visit the company's website: www.allontherapeutics.com.

Forward Looking Statements

There are forward-looking statements contained herein that are not based on historical fact, including without limitation statements containing the words "believes", "may", "plans", "will", "estimate", "continue", "anticipates", "intends", "expects", and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, Allon's stage of development, lack of product revenues, additional capital requirements, risks associated with the completion of clinical trials and obtaining regulatory approval to market Allon's products, the ability to protect its intellectual property and dependence on collaborative partners. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments.

Contact Information